jfm1330 wrote: You know like me that they cannot say stuff to a little group of investors or potential investors and not to the market as a whole. They decided to wait until the MTD is determined to do a press release, that's their choice. Now, it's taking so long that the quaterly CC will force them to give us some kind of an update on the trial. At least they will tell us at what dose they are right now and why it takes so long. I am not sure they will want to disclose efficacy data, positive or negative.
I think the actual low volumes are the consequence of how long this phase Ia is taking and the fact that they stated in the corporate presentation in January that they were still at 420 mg/m2. The delay is not the problem. The problem is that they were still at 420 mg/m2 in January. If they would have been at 742 mg/m2 it would have been another story. At least we could say, yes, it takes time, but they go to very a very high dose, but as far as we know, it is not the case.
They took three months to still be at the same dose, 420 mg/m2. This is confusing. They were at 420 mg/m2 at the beginning of November, and close to four months later, all we know is that are still at that same dose. Also, If I remember well, Levesque said in a call last summer that if they would see efficacy they would report it in the fall, and since then, we heard nothing. Is it because they are not seeing any efficacy signs or because they changed their minds and want to come out with a big news with full data, including correlation with sortilin expression?
There are other signs that seems to be positive, what you told us about positive meetings with big investors, hiring of a siRNA specialist and other hirings. But other than that we are in the dark, and the longer it takes, doubts creep in. So I think it's because of how long it takes that volume is low and SP drifting to lower level.
SPCEO1 wrote: It is nearly 1PM and less than 4,000 shares have traded in THTX today. With an important conference call next Thursday where there is a chance the company might give us a substantive update on the phase 1a, the lack of interest in the stock highlights management's utter failure in calling investors attention to the stock. It seems to me that management has done a pretty good job on most other fronts, but has really not even come close to figuring out how to manage the narrative investors hear about THTX. Of course, if you go several months saying nothing, there is not much managing that can be done!
Nevertheless, as JFM repeatedly reminds us, the data will move the stock. But it would move further if TH got its act together in the all important area of cultivating an interested audience in the stock who was prepared to react in a big way to any big news the company shares.